Advertisement

Ophthalmology

Advertisement

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., and Ube Corp. have received FDA approval for their Omlonti 0.002 percent eye drops, which are designed to reduce elevated intraocular pressure in glaucoma patients. 

EyeSouth Partners will add 19 new physicians before the end of 2022 across 14 of its practices nationwide. 

Advertisement